title: Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults.
abstract: BACKGROUND
  Preliminary data demonstrate that the recurrence of hepatitis C is more severe in patients undergoing adult-to-adult living liver (AAL) transplantation (Tx) in comparison with cadaveric liver (CL) Tx. The authors report on the 1-year follow-up of their cohort of hepatitis C virus (HCV) patients undergoing AALTx or CLTx.
  
  
  METHODS
  Twenty-six patients with HCV end-stage liver cirrhosis underwent CLTx and 17 underwent AALTx. The diagnosis of recurrent HCV was made on the basis of increased transaminases, detectable HCV RNA levels, and histologic findings on liver biopsy. Liver biopsies were performed on the basis of clinical indications. Bilirubin concentration, partial thromboplastin time, and alanine aminotransferase activity were compared between the two groups at different time intervals.
  
  
  RESULTS
  HCV recurrence was seen in 10 of 26 CLTx patients versus 6 of 17 AALTx patients (P=0.1). Time until recurrence was longer in AALTx patients (158+/-114 days vs. 227+/-154 days, P=0.4). Of the biochemical parameters, only bilirubin concentration at week 4 was significantly different between AALTx and CLTx patients (3.1+/-4.3 mg/dL vs. 1.26+/-0.83 mg/dL, P=0.04). Overall survival and the number of patients needing retransplantation were similar in both groups.
  
  
  CONCLUSIONS
  At a follow-up period of 1 year, there is no difference in outcome between end-stage HCV patients undergoing AALTx or CLTx.
authors.affiliation: Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium. hans.vanvlierberghe@ugent.be
authors.forename: H
authors.initials: H
authors.lastname: Van Vlierberghe
authors.forename: R
authors.initials: R
authors.lastname: Troisi
authors.forename: I
authors.initials: I
authors.lastname: Colle
authors.forename: S
authors.initials: S
authors.lastname: Ricciardi
authors.forename: M
authors.initials: M
authors.lastname: Praet
authors.forename: B
authors.initials: B
authors.lastname: de Hemptinne
mesh_terms: D000328:Adult; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D002102:Cadaver; D006528:Carcinoma, Hepatocellular / Q000601:surgery / Q000821:virology; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000401:mortality / Q000473:pathology / Q000502:physiology*; D019520:Living Donors; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D012008:Recurrence; D016019:Survival Analysis; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D001663:Bilirubin